Faeth Therapeutics posts $186.4M cash and announces Q2 2026 results
Faeth Therapeutics' cash surged due to a $200M PIPE financing, with top-line Phase 2 data from the PIK-201 trial in endometrial cancer expected year-end, starkly contrasting with its previous $21.2M cash position.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day